"Although the denials of Juno and Biogen were certainly disappointing, practitioners and patent holders may be glad to have the Court grant certiorari on at least one half of the disclosure requirements in Section 112(a) by way of Amgen."It's that time again.As 2022 has come and (almost) gone, it's time to look back at the exciting grants and surprising denials of certiorari petitions involving patent and trademark matters by the Supreme Court of the United States, and what to look forward to from the Court in 2023.
#back #united-states #flexibility #replacement #supreme-court #consideration #manufacturing #intellectual-property #subject-matter
[
add
]
[
|
|
...
]